Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$6.4 million.

  • Fortress Biotech's Change in Accured Expenses rose 43.33% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 31.49%. This contributed to the annual value of -$6.4 million for FY2024, which is 73.79% up from last year.
  • Fortress Biotech's Change in Accured Expenses amounted to -$6.4 million in FY2024, which was up 73.79% from -$24.4 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Change in Accured Expenses ranged from a high of $43.3 million in FY2021 and a low of -$24.4 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is -$7.5 million, with a median of -$6.4 million in 2024.
  • Per our database at Business Quant, Fortress Biotech's Change in Accured Expenses skyrocketed by 429.88% in 2020 and then plummeted by 392.03% in 2023.
  • Fortress Biotech's Change in Accured Expenses (Yearly) stood at $11.1 million in 2020, then spiked by 290.12% to $43.3 million in 2021, then plummeted by 80.72% to $8.3 million in 2022, then crashed by 392.03% to -$24.4 million in 2023, then spiked by 73.79% to -$6.4 million in 2024.